Biliary excretion of olmesartan, an anigotensin II receptor antagonist, in the rat

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 5, 2005, Pages 784-788

  Takayanagi, Motoe ^a   Sano, Naoyo ^a   Takikawa, Hajime ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bile acids; Eisai hyperbilirubinemic rats (EHBR); Multidrug resistance protein 2; Olmesartan (RNH 6270); P glycoprotein

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BROMSULFOPHTHALEIN; CEFPIRAMIDE; MULTIDRUG RESISTANCE PROTEIN 2; OLMESARTAN; PHENOTHIAZINE; PRAVASTATIN; TAUROCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; VINBLASTINE;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EXCRETION; DRUG INHIBITION; DRUG TRANSPORT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RAT;

EID: 19544392010     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03792.x     Document Type: Article

References (24)

1. Paulusma CC, Bosma PJ, Zaman GJ et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996; 271: 1126-8.
2. Buchler M, Konig J, Brom M et al. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 1996; 271: 15091-8.
3. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, Sugiyama Y. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am. J. Physiol. 1997; 272: G16-22.
4. Paulusma CC, Kool M, Bosma PJ et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997; 25: 1539-42.
5. Wada M, Toh S, Taniguchi K et al. Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum. Mol Genet. 1998; 7: 203-7.
6. Gerloff T, Stieger B, Hagenbuch B et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 1998; 273: 10046-50.
7. Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J. Biol. Chem. 1989; 264: 11693-8.
8. Mizuno M, Sada T, Ikeda M et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol. 1995; 285: 181-8.
9. Takemoto M, Egashira K, Tomita H et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621-7.
10. Puchler K, Nussberger J, Laeis P, Witte PU, Brunner HR. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J. Hypertens. 1997; 15: 1809-12.
11. Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens. Res. 2001; 24: 641-6.
12. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type ATI receptor antagonist. J. Hypertens. 2001; 19: S3-14.
13. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J. Hum. Hypertens. 2002; 16: S13-16.
14. Watanabe T, Suzuki H, Sawada Y et al. Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J. Hepatol. 1995; 23: 440-8.
15. Sato A, Takikawa H, Yamanaka M. Effects of organic anions and vinblastine on biliary excretion of erythromycin in rats. Pharmacology 1999; 59: 249-56.
16. Suzuki Sano N, Takikawa H. Effect of dexamethasone on biliary excretion of bile acids and organic anions in rats. Hepatol. Res. 2003; 25: 48-54.
17. Takikawa H, Uchida Y, Sano N, Yamanaka M. Biliary cefpiramide excretion: its relation to biliary excretion of bile acids and sulfobromophthalein. Pharmacology 1995; 51: 24-32.
18. Fukumura S, Takikawa H, Yamanaka M. Effects of organic anions and bile acid conjugates on biliary excretion of pravastatin in the rat. Pharm. Res. 1998; 15: 72-6.
19. Takikawa H, Sano N, Yamanaka M. Effects of ursodeoxycholate and its conjugates on biliary glutathione excretion in rats. Dig. Dis. Sci. 1996; 41: 1953-8.
20. Takikawa H, Wako Y, Sano N, Yamanaka M. Changes in biliary excretory mechanisms in bile duct-ligated rat. Dig. Dis. Sci. 1993; 41: 256-62.
21. Takikawa H, Sano N, Marita R et al. Biliary excretion of bile acid conjugates in hyperbilirubinemic mutant Sprague-Dawley rats. Hepatology 1991; 14: 352-60.
22. Yamazaki M, Akiyama S, Niinuma K, Nishigaki R, Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT). Drug Metab. Dispos. 1997; 25: 1123-9.
23. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000; 118: 422-30.
24. Hanawa N, Sano N, Takikawa H. Biliary excretion of azelnidipine, a calcium antagonist, in rats. J. Gastroenterol. Hepatol. 2004; 19: 413-17.